Consequently, elevated amounts of TNF-α, IL-2, and IFN-γ were produced by CAR-T cells treatment only in CLDN18.2-positive cancer cells, where predominant CD8+ T cells were evidenced, corroborating a persistent and highly tumor-infiltrating CAR-T therapy [129]. The gene discussed is CD8A; the disease is cancer.